204-235-3206 info@sbrc.ca
Select Page
Dr. Davinder S. Jassal

Dr. Davinder S. Jassal

Principal Investigator
Cardiovascular Imaging, Institute of Cardiovascular Sciences

Professor
Department of Internal Medicine, University of Manitoba

Research Focus

Dr. Jassal’s research focuses on the complementary use of multimodality non-invasive cardiovascular imaging in the assessment of heart failure syndromes. Using a combination of echocardiography (ultrasound of the heart), cardiac CT (computed tomography), and CMR (cardiac MRI), the Cardiovascular Imaging Laboratory at the St. Boniface Albrechtsen Research Centre is dedicated to translational research in the fields of Cardio-Oncology, Women’s Heart Health, and Sudden Cardiac Death.

1. EMPACT-BC study (Empagliflozin in the prevention and treatment of doxorubicin and trastuzumab mediated cardiotoxicity in breast cancer)

Breast cancer is a major public health concern in Canada. Doxorubicin and Trastuzumab (DOX+TRZ) are two of the most common anti-cancer drugs used in the treatment of breast cancer. While these two anti-cancer drugs improve survival in the breast cancer setting, they may also increase the risk of developing heart failure. Approximately 1 in 4 women with breast cancer are at risk of developing heart failure due to DOX+TRZ, affecting over 8000 women annually in Canada. In the present “EMPACT-BC” study, we will explore the role of the medication “Empagliflozin” in both preventing and treating heart failure caused by DOX+TRZ. Once we obtain this important information from our murine model, we will translate these basic science findings into a multi-centre randomized controlled trial to further investigate the preventative and treatment effects that Empagliflozin may have in individuals with breast cancer. This innovative study will enhance the quality of “heart health” in women with breast cancer.

2. CANFLAX study (Can flax “milk” prevent broken hearts in women with breast cancer?)

As Manitoba continues to be one of the top flaxseed (FLX) producers in the world, there is increasing public awareness about the importance of consuming this whole grain commodity in the prevention of cancer and cardiovascular disease. Given that women with breast cancer are at risk of developing chemotherapy-induced heart failure, FLX has demonstrated a promising capacity to prevent this adverse outcome. Pizzey Ingredient’s FLX “milk” is a breakthrough advancement for dietary FLX, providing an efficient and delicious way to consume over 30 g of FLX on a daily basis. FLX “milk”, with its cardioprotective components, including omega-3 fatty acid, alpha-linolenic acid, and plant lignans, is a new alternative in this expanding global market of non-dairy “milk” products. The purpose of the CANFLAX study is to establish FLX “milk” as an effective method of preventing heart failure in women with breast cancer undergoing anthracycline-based chemotherapy. Researching the health benefits of FLX “milk” in this study will help generate: i) an increase in consumer interest; ii) an increase in the demand for FLX; and iii) an increase in FLX acreage within Manitoba. Overall, Manitoba-produced FLX “milk” is an ideal product to prevent broken hearts in women with breast cancer.

3. EXACT 2.0 (Exercise to prevent anthracycline-based cardio-toxicity in individuals with breast cancer)

This past year, 27,000 Canadian women were diagnosed with breast cancer. Although significant advances in the battle against breast cancer have resulted in improved morbidity and mortality among women with breast cancer, certain chemotherapy drugs such as anthracyclines (AC) are notorious for causing heart failure. Discovering novel ways to reduce the damaging effects of AC chemotherapy without interfering with the anti-cancer efficacy remain at the forefront of our research. Recent pre-clinical studies have shown that aerobic exercise (AE) performed before or during AC chemotherapy can protect the heart from the damaging effects of these anti-cancer agents. However, the benefits of AE have not been demonstrated in women receiving cancer treatment in the clinical setting. As such, this study seeks to understand the potential benefits of a home-based AE program on the cardiovascular profile in women with breast cancer treated with AC chemotherapy. Patients will be randomly assigned to either the AE or the standard of the care control group. Women with breast cancer assigned to AE will receive a 12-week, home-based exercise program. Contemporary cardiac imaging modalities will be used to assess cardiac function throughout the EXACT 2.0 study. The primary goal of this study is to elucidate how an AE program affects: 1) changes in heart structure (ultrasound of the heart); 2) cardiac electrical activity (ECG); and 3) peak oxygen consumption (VO2 max.). Given that anthracycline-based chemotherapy continues to be routinely used, this study is an invaluable first step to protecting the hearts of women with breast cancer.

About Dr. Davinder S. Jassal

Dr. Jassal was born in Thompson, Manitoba, Canada, obtained an International Baccalaureate Degree at Sisler High School in Winnipeg, and graduated from the University of Manitoba with an MD in 1998. He completed a residency in Internal Medicine at the University of Manitoba from 1998-2001 and a residency in Adult Cardiology at Dalhousie University in Halifax, Nova Scotia, Canada. Subsequently, he completed a clinical and research fellowship in Cardiac Imaging specializing in echocardiography, CT, and MRI at Massachusetts General Hospital, Harvard Medical School, Boston, MA.

Dr. Jassal joined the Section of Cardiology, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences at the University of Manitoba in 2006 as an Academic Clinician Scientist, where half of his time is devoted to patient care in the acute cardiac care unit (ACCU) and cardiac imaging and the other half devoted to translational research in the field of Cardio-Oncology. He is currently Full Professor of Medicine, Radiology, and Physiology and Pathophysiology. As Head of the Section of Cardiology in the Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, at the University of Manitoba, Dr. Jassal is also a member of the Institute of Cardiovascular Sciences as the Principal Investigator of the Cardiovascular Imaging Laboratory.

 

For more information, please contact:

Dr. Davinder S. Jassal
Rm. 4010, St. Boniface Hospital Research, 351 Tache, R2H 2A6
Lab Phone. (204) 237-2599
Lab Office. (204) 235-3056
Hospital Office. (204) 258-1290
Fax. (204) 233-2157
Email. djassal@sbgh.mb.ca

Mr. David YC Cheung
Research Technician
Rm. 4010, St. Boniface Hospital Research, 351 Tache, R2H 2A6
Lab Phone. (204) 237-2599, (204) 235-3741
Fax. (204) 233-6723
Email. dcheung@sbrc.ca

Ms. Allison Ledingham
Research Technician
Rm. 4010, St. Boniface Hospital Research, 351 Tache, R2H 2A6
Lab Phone. (204) 237-2599, (204) 235-3741
Fax. (204) 233-6723
Email. aledingham@sbrc.ca

2023

  1. Nair P, Chen-Tournoux A, Almufleh AS, Blissett S, Ducas R, Fine NM, Johri AM, Kushneriuk D, Ramer S, Sanfilippo A, Thibodeau-Jarry N, Yu E, Bewick D, Burwash IG, Chow CM, Cooley H, De S, Douflé G, Fagan SM, Henri C, Jassal DS, Jelic T, Lee D, Leipsic J, Leong-Poi H, Luksun W, Mulloy AJ, Mulvagh S, Nesbitt G, Promislow S, Sebag IA, Tran DTT, Tsang TSM. 2023 CCS/CSE Standards for Physician Training and Maintenance of Competence in Adult Echocardiography: Executive Summary. Can J Cardiol. 2023 Jun 22:S0828-282X(23)01448-4. doi: 10.1016/j.cjca.2023.06.418.
  2. Su S, Shah P, Jassal DS. Ventricular tachycardia triggered by electroconvulsive therapy: Case report and review of the literature. Clin Case Rep. 2023 May 29;11(6):e7450. doi: 10.1002/ccr3.7450. eCollection 2023 Jun.
  3. Hassan-Tash P, Ismail U, Kirkpatrick IDC, Ravandi A, Jassal DS, Hiebert B, Kass M, Krasuski RA, Shah AH. Correlation of Impedance Cardiography-Derived and Cardiac Magnetic Resonance-Derived Stroke Volumes. Curr Probl Cardiol. 2023 Feb;48(2):101457. doi: 10.1016/j.cpcardiol.2022.101457. Epub 2022 Oct 21. PMID: 36273652.

2022

  1. Nagalingam RS, Chattopadhyaya S, Al-Hattab DS, Cheung DYC, Schwartz LY, Jana S, Aroutiounova N, Ledingham DA, Moffatt TL, Landry NM, Bagchi RA, Dixon IMC, Wigle JT, Oudit GY, Kassiri Z, Jassal DS, Czubryt MP. Scleraxis and fibrosis in the pressure-overloaded heart. Eur Heart J. 2022 Dec 1;43(45):4739-4750. doi: 10.1093/eurheartj/ehac362.
  2. Dhingra R, Rabinovich-Nikitin I, Rothman S, Guberman M, Gang H, Margulets V, Jassal DS, Alagarsamy KN, Dhingra S, Valenzuela Ripoll C, Billia F, Diwan A, Javaheri A, Kirshenbaum LA. Proteasomal Degradation of TRAF2 Mediates Mitochondrial Dysfunction in Doxorubicin-Cardiomyopathy. Circulation. 2022 Sep 20;146(12):934-954. doi: 10.1161/CIRCULATIONAHA.121.058411. Epub 2022 Aug 19.
  3. Al-Shudiefat AA, Ludke A, Malik A, Jassal DS, Bagchi AK, Singal PK. Olive oil protects against progression of heart failure by inhibiting remodeling of heart subsequent to myocardial infarction in rats. Physiol Rep. 2022 Aug;10(15):e15379. doi: 10.14814/phy2.15379.
  4. Bews H, Bryson A, Bortoluzzi T, Tam JW, Jassal DS. COVID-19 Vaccination-Induced Myopericarditis: An Imager’s Perspective. CJC Open. 2022 May;4(5):497-500. doi: 10.1016/j.cjco.2022.01.007. Epub 2022 Jan 29.
  5. Eekhoudt C. R, Bortoluzzi T, Varghese S. S, Cheung D.Y.C, Christie S, Eastman S, Mittal I, Austria J. A, Aukema H. M, Ravandi A, Thliveris J, Singal PK, Jassal DS. Comparing Flaxseed and Perindopril in the Prevention of Doxorubicin and Trastuzumab-Induced Cardiotoxicity in C57Bl/6 Mice. Curr. Oncol. 2022 Apr; 29:2941-2953.
  6. Malik A, Bagchi AK, Jassal DS, Singal PK. Interleukin-10 mitigates doxorubicin-induced endoplasmic reticulum stress as well as cardiomyopathy. Biomedicines. 2022 Apr13;10(4):890. Doi: 10.3390/biomedicines10040890.
  7. Kirkham AA, Pituskin E, Thompson RB, Mackey JR, Koshman SL, Jassal D, Pitz M, Haykowsky MJ, Pagano JJ, Chow K, Tsui AK, Ezekowitz JA, Oudit GY, Paterson DI. Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: a secondary analysis of the MANTICORE trial. Eur Heart J Cardiovasc Pharmacother. 2022 Feb 16;8(2):130-139. doi: 10.1093/ehjcvp/pvab016.

2021

  1. Bews H, Bortoluzzi T, Jassal DS. Coronary stent on the move. Eur Heart J Case Rep. 2021 Dec 14;5(12):ytab511. doi: 10.1093/ehjcr/ytab511. eCollection 2021 Dec.
  2. Bagchi AK, Malik A, Akolkar G, Jassal DS, Singal PK. Endoplasmic reticulum stress promotes iNOS/NO and influence inflammation in the development of doxorubicin-induced cardiomyopathy. Antioxidants. 2021 Nov 26;10(12):1897. doi: 10.3390/antiox10121897.
  3. Varghese SS, Johnston WJ, Eekhoudt CR, Keats MR, Jassal DS, Grandy SA. Exercise to reduce anthracycline-mediated cardiovascular complications in breast cancer survivors. Current Oncology. 2021 Oct 13;28(5):4139-4156. doi: 10.3390/curroncol28050351.
  4. Paterson I, Ramanathan K, Aurora R, Bewick D, Chow CM, Clarke B, Cowan S, Ducharme A, Gin K, Graham M, Gupta A, Jassal DS, Kazmi M, Krahn A, Lamarche Y, Marelli A, Roifman I, Ruel M, Singh G, Sterns L, Turgeon R, Virani S, Wong KK, Zieroth S. Long COVID-19: A Primer for Cardiovascular Health Professionals On Behalf of the CCS Rapid Response Team. Can J Cardiol. 2021 Jun 3:S0828-282X(21)00287-7. doi: 10.1016/j.cjca.2021.05.011
  5. Bagchi AK, Malik A, Akolkar G, Zimmer A, Belló-Klein A, De Angelis K, Jassal DS, Fini MA, Stenmark KR, Singal PK. Study of ER stress and apoptotic proteins in the heart and tumor exposed to doxorubicin. Biochim Biophys Acta Mol Cell Res. 2021 Jun;1868(7):119039. doi: 10.1016/j.bbamcr.2021.119039
  6. Koleini N, Nickel BE, Nagalingam RS, Landry NM, Fandrich RR, Cheung DYC, Dixon IM, Czubryt MP, Jassal DS, Cattini PA, Kardami E. Elimination of endogenous high molecular weight FGF2 prevents pressure-overload-induced systolic dysfunction, linked to increased FGFR1 activity and NR1D1 expression Cell Tissue Res. 2021 May 31. In press.
  7. Malik A, Bagchi AK, Vinayak K, Akolkar G, Slezak J, Belló-Klein A, Jassal DS, Singal PK. Vitamin C: historical perspectives and heart failure. Heart Fail Rev. 2021 May;26(3):699-709. doi: 10.1007/s10741-020-10036-y. Epub 2020 Oct 8.
  8. Ferreira EO, MacDonald JK, Jassal DS, Rhee DD. Atypical presentation of Takayasu aortitis and myocarditis contributing to sudden death in a young Canadian first nations adult. Cardiovasc Pathol. 2021 May 24:107347. doi: 10.1016/j.carpath.2021.107347. Online ahead of print. PMID: 34038802
  9. Roifman I, Arora RC, Bewick D, Chow CM, Clarke B, Cowan S, Ducharme A, Gin K, Graham M, Gupta A, Hardiman S, Hartleib M, Jackson S, Jassal DS, Kazmi M, Lamarche Y, Légaré JF, Leong-Poi H, Mansour S, Marelli A, Ruel M, Small G, Sterns L, Turgeon R, Virani S, Wijeysundera HC, Wong K, Wood DA, Zieroth S, Singh G, Krahn AD. Cardiovascular Care Delivery During the Second Wave of COVID-19 in Canada. Can J Cardiol. 2021 May;37(5):790-793. doi: 10.1016/j.cjca.2020.11.016. Epub 2020 Dec 9. PMID: 33307163
  10. Varghese SS, Eekhoudt CR, Jassal DS. Mechanisms of anthracycline-mediated cardiotoxicity and preventative strategies in women with breast cancer. Mol Cell Biochem. 2021 Apr 9. doi: 10.1007/s11010-021-04152-y.
  11. McAndrew EN, Jassal DS, Goldenberg BA, Kim CA. Capecitabine-mediated heart failure in colorectal cancer: a case series.  Eur Heart J Case Rep. 2021 Mar 2;5(3):ytab079. doi: 10.1093/ehjcr/ytab079. eCollection 2021 Mar.
  12. Lee CT, Eastman SE, Arcinas LA, Asselin CY, Cheung D, Mayba A, Zhu A, Strzelczyk J, Maycher B, Memauri B, Kirkpatrick IDC, Jassal DS. Prevalence and Functional Implication of Silent Coronary Artery Disease in Marathon Runners Over 40 Years of Age: The MATCH-40 Study. CJC Open. 2021 Jan 7;3(5):595-602. doi: 10.1016/j.cjco.2020.12.024. eCollection 2021 May. PMID: 34027364

2020

  1. Surendran A, Edel A, Chandran M, Bogaert P, Hassan-Tash P, Kumar Asokan A, Hiebert B, Solati Z, Sandhawalia S, Raabe M, Kass M, Shah A, Jassal DS, Jaleel A, Ravandi A. Metabolomic Signature of Human Aortic Valve Stenosis. JACC Basic Transl Sci. 2020 Dec 16;5(12):1163-1177. doi: 10.1016/j.jacbts.2020.10.001. eCollection 2020 Dec.

  2. Sin PS, Jassal DS, Luqman Z, Kirkpatrick ID, Ravandi A, Kass M. “Tear in my Heart”: A Multimodality Perspective. CJC Open. 2020 Oct 8;3(2):225-226. doi: 10.1016/j.cjco.2020.09.025. eCollection 2021 Feb.

  3. Guillemette L, Wicklow B, Sellers EAC, Dart A, Shen GX, Dolinsky VW, Gordon JW, Jassal DS, Nickel N, Duhamel TA, Chateau D, Prior HJ, McGavock J. Intrauterine exposure to diabetes and risk of cardiovascular disease in adolescence and early adulthood: a population-based birth cohort study. CMAJ. 2020 Sep 28;192(39):E1104-E1113. doi: 10.1503/cmaj.190797

  4. Asselin CY, Lam A, Cheung DYC, Eekhoudt CR, Zhu A, Mittal I, Mayba A, Solati Z, Edel A, Austria JA, Aukema HM, Ravandi A, Thliveris J, Singal PK, Pierce GN, Niraula S, Jassal DS. The Cardioprotective Role of Flaxseed in the Prevention of Doxorubicin- and Trastuzumab-Mediated Cardiotoxicity in C57BL/6 Mice. J Nutr. 2020 Jun 8:nxaa144. doi: 10.1093/jn/nxaa144.

  5. Ho J, Toleva O, Jassal DS, Khoo C. Atypical Cardiac Manifestations of Systemic Myositis. J Clin Rheumatol. 2020 Aug;26(5):e121. doi: 10.1097/RHU.0000000000000992.

  6. Parr CJ, Kass M, Yamashita MH, Jassal DS. Thrombosis of a mechanical mitral valve: a sticky situation. Eur Heart J. 2020 Aug 1;41(29):2816. doi: 10.1093/eurheartj/ehaa126.

  7. Bagchi AK, Surendran A, Malik A, Jassal DS, Ravandi A, Singal PK. IL-10 attenuates OxPCs-mediated lipid metabolic responses in ischemia reperfusion injury. Sci Rep. 2020 Jul 21;10(1):12120. doi: 10.1038/s41598-020-68995-z.

  8. Zhu A, Bews H, Cheung D, Nagalingam RS, Mittal I, Goyal V, Asselin C, Kirkpatrick I, Czubryt MP, Jassal DS. Scleraxis as a Prognostic Marker of Myocardial Fibrosis in Hypertrophic Cardiomyopathy (SPARC) Study. Can J Physiol Pharmacol. 2020 Jul;98(7):459-465. doi: 10.1139/cjpp-2019-0636. Epub 2020 Feb 6.

  9. Ismail U, Toleva O, Jassal DS. The first appearance deceives many: Isolated RV infarct masquerading as an anterior STEMI. Clin Case Rep. 2020 Jun 23;8(10):2090-2091. doi: 10.1002/ccr3.3061. eCollection 2020 Oct.

  10. Eekhoudt CR, Hebbard P, Tan L, Qiu H, Jassal DS. Peripheral Malignant Nerve Sheath Tumour: At the Heart of the Matter. Can J Cardiol. 2020 Jun;36(6):967.e21-967.e22. doi: 10.1016/j.cjca.2019.11.015.

  11. Guillemette L, Dart A, Wicklow B, Dolinsky VW, Cheung D, Jassal DS, Sellers EAC, Gelinas J, Eves ND, Balshaw R, Agarwal P, Duhamel TA, Gordon JW, McGavock JM. Cardiac structure and function in youth with type 2 diabetes in the iCARE cohort study: Cross-sectional associations with prenatal exposure to diabetes and metabolomic profiles. Pediatr Diabetes. 2020 Mar;21(2):233-242. doi: 10.1111/pedi.12954. 

2019

  1. Lau L, Wiens EJ, Karlowsky JA, Keynan Y, Jassal DS. Clinical utility of echocardiography for the diagnosis of native valve infective endocarditis in Staphylococcus aureus bacteremia. Echocardiography. 2019 Oct;36(10):1852-1858. doi: 10.1111/echo.14480.

  2. Sharma R, Bews H, Mahal H, Asselin CY, O’Brien M, Koley L, Hiebert B, Ducas J, Jassal DS. In-Hospital Cardiac Arrest in the Cardiac Catheterization Laboratory: Effective Transition from an ICU- to CCU-Led Resuscitation Team. J Interv Cardiol. 2019 Sep 2;2019:1686350. doi: 10.1155/2019/1686350.

  3. Morissette MP, Susser SE, Stammers AN, Moffatt TL, Wigle JT, Wigle TJ, Netticadan T, Premecz S, Jassal DS, O’Hara KA, Duhamel TA. Exercise-induced increases in the expression and activity of cardiac sarcoplasmic reticulum calcium ATPase 2 is attenuated in AMPKα2 kinase-dead mice. Can J Physiol Pharmacol. 2019 Aug;97(8):786-795. doi: 10.1139/cjpp-2018-0737.

  4. Abdelfatah N, Chen R, Duff HJ, Seifer CM, Buffo I, Huculak C, Clarke S, Clegg R, Jassal DS, Gordon PMK, Ober C; Care4Rare Canada Consortium, Frosk P, Gerull B. Characterization of a Unique Form of Arrhythmic Cardiomyopathy Caused by Recessive Mutation in LEMD2. JACC Basic Transl Sci. 2019 Apr 29;4(2):204-221. doi: 10.1016/j.jacbts.2018.12.001.

  5. Jassal DS. Cardio-Oncology: A Tale of Two Cities: The art of preventing broken hearts in women with breast cancer. Clin Invest Med. 2019 Mar 23;42(1):E13-E18. doi: 10.25011/cim.v42i1.32385.

  6. Chu K, Asselin CY, Buffo I, Lane M, Ludwig L, Jassal DS, Schantz D. The Role of Cardiac Magnetic Resonance Imaging in Severe Anorexia Nervosa. Cureus. 2019 Mar 11;11(3):e4229. doi: 10.7759/cureus.4229.
  7. Luu J, Boston-Griffiths E, Zhu A, Jassal DS, Minhas K. Colossal left ventricular apical thrombus. Clin Case Rep. 2019 Mar 3;7(4):846-848. doi: 10.1002/ccr3.2081.

  8. Mozolevska V, Schwartz A, Cheung D, Goyal V, Shaikh B, Dingman B, Kim E, Mittal I, Asselin CY, Edel A, Ravandi A, Thliveris J, Singal PK, Czaykowski P, Jassal DS. Role of renin-angiotensin system antagonists in the prevention of bevacizumab- and sunitinib-mediated cardiac dysfunction. Am J Physiol Heart Circ Physiol. 2019 Mar 1;316(3):H446-H458. doi: 10.1152/ajpheart.00344.2018.

  9. Nhola LF, Abdelmoneim SS, Villarraga HR, Kohli M, Grothey A, Bordun KA, Cheung M, Best R, Cheung D, Huang R, Barros-Gomes S, Pitz M, Singal PK, Jassal DS, Mulvagh SL. Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers. J Am Soc Echocardiogr. 2019 Feb;32(2):267-276. doi: 10.1016/j.echo.2018.09.019.

  10. Koleini N, Santiago JJ, Nickel BE, Sequiera GL, Wang J, Fandrich RR, Jassal DS, Dhingra S, Kirshenbaum LA, Cattini PA, Kardami E. Elimination or neutralization of endogenous high-molecular-weight FGF2 mitigates doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol. 2019 Feb 1;316(2):H279-H288. doi: 10.1152/ajpheart.00587.2018. Epub 2018 Nov 9.

  11. Ho J, Toleva O, Jassal DS, Khoo C. Atypical Cardiac Manifestations of Systemic Myositis. J Clin Rheumatol. 2019 Jan 18. doi: 10.1097/RHU.0000000000000992.

  12. Yeang C, Hasanally D, Que X, Hung MY, Stamenkovic A, Chan D, Chaudhary R, Margulets V, Edel AL, Hoshijima M, Gu Y, Bradford W, Dalton N, Miu P, Cheung DY, Jassal DS, Pierce GN, Peterson KL, Kirshenbaum LA, Witztum JL, Tsimikas S, Ravandi A. Reduction of myocardial ischaemia-reperfusion injury by inactivating oxidized phospholipids. Cardiovasc Res. 2019 Jan 1;115(1):179-189. doi: 10.1093/cvr/cvy136.

  13. Yeang C, Hasanally D, Que X, Hung MY, Stamenkovic A, Chan D, Chaudhary R, Margulets V, Edel AL, Hoshijima M, Gu Y, Bradford W, Dalton N, Miu P, Cheung DY, Jassal DS, Pierce GN, Peterson KL, Kirshenbaum LA, Witztum JL, Tsimikas S, Ravandi A. Reduction of myocardial ischaemia-reperfusion injury by inactivating oxidized phospholipids. Cardiovasc Res. 2019 Jan 1;115(1):179-189. doi: 10.1093/cvr/cvy136.

2021

St. Boniface Hospital Ron Duhamel Innovation Award

 

2019

Manitoba Medical students Association Teaching Award Nominee for Pre-Clerkship Mentor and Best Teaching in small group setting

  1. CancerCare Manitoba Operating Grant 2022-2024
    Title: Empagliflozin in the prevention and treatment of doxorubicin and trastuzumab mediated cardiotoxicity in breast cancer (EMPACT-BC)

 

  1. CAN-USA grant 2022-2024
    Title: The cardioprotective role of SGLT2 inhibition in the prevention of anthracycline mediated heart failure (SHIELD-HF)

 

  1. Heart and Stroke Foundation of Canada 2019-2022
    Title: Flaxseed in the prevention and treatment of anthracycline and trastuzumab mediated cardiotoxicity

 

  1. Canadian Agricultural Partnership/ Ag Action Manitoba 2019-2023
    Title: Flaxseed prevents broken hearts in breast cancer (CANFLAX) study

 

  1. Canadian Cancer Society/ CIHR Grant Innovation (Co-applicant) 2018-2024
    Title: Exercise to prevent AnthraCycline-based Cardio-Toxicity (EXACT 2.0) in individuals with breast cancer 

 

  1. Molson Women’s Heart Health Research competition 2018-2022
    Title: Reducing cardiovascular risk in women with breast cancer

 

  1. University Collaborative Research Program (UCRP) 2018-2020
    Title: Role of cardiac CT for risk stratification in the marathon population

 

  1. CancerCare Manitoba Operating Grant 2017-2020
    Title: Flaxseed in the mitigation of anthracycline and trastuzumab mediated cardiotoxicity (FANTAM) study

 

  1. Diagnostic Services Manitoba 2017-2019
    Title: Scleraxis as a biomarker for cardiac fibrosis in hypertrophic cardiomyopathy

 

  1. CIHR Operating grant (Co-applicant) 2015-2020
    Title: The role of FGF2 isoforms in cardiac remodeling

 

  1. Research Manitoba Mid-Career research grant 2015-2019
    Title: The prophylactic role of RAS inhibition in the prevention of Avastin and Sutent induced cardiotoxicity

Media

Life In the Lab

Jassal Lab - 2022
Jassal Lab 2019
Group photo from Dr. Jassal's lab.
Jassal lab group photo
Dr. Jassal's lab
Dr. Jassal lab group photo
Dr. Jassal lab group photo
Dr. Jassal lab group photo
Dr. Jassal lab group photo